-

Thermo Fisher Scientific Launches the Krios 5 Cryo-Transmission Electron Microscope (TEM), Boosting Productivity and Performance With Enhanced Automation

The new Krios 5 Cryo-TEM enables breakthroughs in structural and cellular biology to pioneer new treatments and advance drug discovery

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Krios 5 Cryo-TEM. This next-generation, atomic-resolution platform leverages enhanced optics and AI-enabled automation to study molecular structures and interactions at a throughput and fidelity that was previously unattainable.

A Leap Forward in Imaging and Insight

In the rapidly evolving field of structural biology, single particle analysis (SPA) and cryo-electron tomography (cryo-ET) are powerful techniques that allow scientists to better understand the intricacies of biology, providing atomic-level insights that reveal how viruses, proteins and cells work.

The Krios 5 Cryo-TEM optimizes productivity and performance to enhance these techniques. With a throughput improvement of up to 25% compared to previously released models, the Krios 5 enables 3D visualization of proteins, as well as their interactions and dynamics within the biological cell. Other Krios 5 advantages include AI-powered experimental set-up and upgraded data acquisition. For the cryo-ET workflow, the innovative vacuum capsule transfer helps prevent contamination of samples.

Collectively, these enhancements build on Thermo Fisher’s cryo-EM legacy with a new generation of Krios that will enable researchers to pioneer new treatments and advance drug discovery.

“Our innovation has always been driven by the needs of our customers, and the Krios 5 Cryo-TEM is no exception,” said Trisha Rice, vice president and general manager of life sciences for Materials and Structural Analysis at Thermo Fisher Scientific. “By delivering unparalleled automation and throughput, we are empowering researchers and the pharmaceutical industry to unlock new insights and fight diseases better than ever before.”

Making Science More Sustainable

The Krios 5 has a low-power stand-by mode with rapid wake-up capabilities, minimizing energy consumption while not in use, without delaying experiments. Certified with the My Green Lab ACT Ecolabel, the Krios 5 supports sustainability goals of customers and the scientific community.

To learn more about the Krios 5, please visit our website and register for the product launch webinar on May 14.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Alex Runner
Thermo Fisher Scientific
alex.runner@thermofisher.com

Jessika Parry, Greenough
419-266-4016
jparry@greenoughagency.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Alex Runner
Thermo Fisher Scientific
alex.runner@thermofisher.com

Jessika Parry, Greenough
419-266-4016
jparry@greenoughagency.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom